Product news

Eli Lilly announced that the FDA has approved Cymbalta (duloxetine HCl) for the maintenance treatment of major depressive disorder in adults.

Novartis' Diovan (valsartan), an angiotensin receptor blocker, has been approved following a priority review by the FDA for the treatment of high blood pressure in children and adolescents ages six to 16.

Alcon announced that the FDA has approved Triesence (triamcinolone acetonide injectable suspension) 40 mg/mL, a preservative-free synthetic corticosteroid for visualization during vitrectomy and treatment of sympathetic ophthalmia, temporal arteritis, uveitis, and ocular inflammatory conditions unresponsive to topical corticosteroids.

You must be a registered member of MMM to post a comment.
 

Did you miss January's Top 40 Healthcare Transformers issue? Read how these inventors, strategists, entrepreneurs and wonks are challenging, disrupting and otherwise transforming the healthcare business. And join us April 30 to honor them at the Transforming Healthcare Dinner. Click here.